

**Table S1: sensitivity analysis for the association between RA treatments and risk of lymphoma in cases with RA diagnosis in the same period than their controls in the ESPOIR cohort (2002-2005)**

	Cases (N=8)	Controls (N=16)	OR (95%CI)	p-value
<b>Glucocorticoids, N (%)</b>	4 (50.0%)	9 (56.3%)	0.78 (0.10-5.93)	1.00
<b>Methotrexate, N (%)</b>	4 (50.0%)	9 (56.3%)	0.78 (0.10-5.93)	1.00
<b>Hydroxychloroquine, N (%)</b>	5 (50.0%)	2 (12.5%)	6.33 (0.64-95.63)	0.12
<b>Sulfasalazine, N (%)</b>	0 (0.0%)	1 (6.2%)	-	1.00
<b>Leflunomide, N (%)</b>	2 (25.0%)	2 (12.5%)	2.24 (0.13-38.10)	0.58
<b>Other DMARDs, N (%)</b>	1 (12.5%)	0 (0.0%)	-	0.33
<b>TNF-blockers, N (%)</b>	3 (37.5%)	5 (31.3%)	1.30 (0.14-10.51)	1.00
<b>Rituximab, N (%)</b>	1 (12.5%)	0 (0.0%)	-	0.33
<b>Abatacept, N (%)</b>	0 (0.0%)	2 (12.5%)	-	0.54
<b>Tocilizumab, N (%)</b>	0 (0.0%)	1 (6.2%)	-	1.00
<b>Lines of biologics, mean (SD)</b>	0.62 (1.06)	0.5 (0.89)	1.00 (0.83-1.07)	0.78